In recent years there have been significant improvements in rectal cancer outcome. New surgical techniques and effective neoadjuvant treatment regimens have contributed to these improvements. It is important to spread these advances to every rectal cancer patient and to make sure that it is not only patients treated within the framework of clinical trials who may benefit from these advances. Throughout Europe there have been interesting quality programmes that have been proved to facilitate the spread of up-to-date knowledge and skills among medical professionals, resulting in improved treatment outcomes. Despite these laudable efforts, there is still wide variation in treatment outcomes between countries, regions and institutions, which calls for a European audit on cancer treatment outcomes.
a result, several ranking lists can be found on the Internet and in the popular press worldwide. Unfortunately, many of those lists do not meet the requirements needed for a fair comparison of healthcare providers and can therefore give misleading results.
Nevertheless, the search for quality is plausible because there seem to be substantial differences in quality of care between countries, hospitals and doctors. 1 In addition to patients, politicians, insurance companies and medical professionals also strive for a higher quality of care, all with their own reasons and strategies. In many countries, governments have tightened their existing regulations and created new ones when trying to improve quality of care in a 'top-down' manner. Obviously, medical professionals also put great effort into improving their quality of work, but this happens in a 'bottom-up' manner. All initiatives to improve quality of care can be nominated as 'quality assurance'. Although lacking a strict definition, quality assurance can be summarised as "the complete set of systematic actions that is required to achieve a treatment result that meets a certain standard". 2 Quality assurance in surgical oncology is relatively new compared with other medical fields such as chemotherapy and radiotherapy.
For a long time, surgery was thought to have too much unexpected variation to be feasible for standardisation and quality control.
However, the conception of surgery is steadily shifting from being a non-definable craft to a transparent and well-defined skill.
Currently, many quality assurance programmes have been rolled out successfully in surgical oncology with encouraging results, in particular for the treatment of rectal cancer. In the early 1990s, the outcome after rectal cancer surgery was poor, with survival and recurrence rates of approximately 45%. 3 In addition, there was a remarkable variation in outcome between hospitals and between individual surgeons. 4, 5 In that time the total mesorectal excision (TME) technique was introduced by Heald et al. 6 Instead of a blunt dissection, the rectum is sharply dissected within its mesorectal fascia under direct vision. Many European countries initiated quality assurance projects as an answer to these challenges. In this article, we will describe different aspects of quality assurance, and will conclude with a framework for the future of surgical oncology in Europe.
Clinical Trials
Several European studies have shown improvements in outcome after implementation of the TME technique in rectal cancer surgery. 4, 7 This resulted in lasting positive effects. 9 Rectal cancer patients in the region of the Comprehensive Cancer Centres South and West were clustered in three groups: before, during and after the trial period of the TME study (1996) (1997) (1998) (1999) 
Multidisciplinary Treatment
The importance of multidisciplinary treatment cannot be emphasised enough. Even the best surgeon is helpless without an adequate radiologist, pathologist, medical oncologist and radiotherapist. Much effort has been put into the multidisciplinary approach of cancer treatment for rectal cancer patients. Radiologists had to facilitate magnetic resonance imaging diagnostics, whereas pathologists had to adapt according to the protocol of Quirke et al. 12 to adequately identify lateral spread of tumour. Radiotherapists had to shift to preoperative radiation treatment schemes for a majority of patients. It is essential to include all multidisciplinary fields of cancer treatment in quality assurance programmes by standardising, training and visitation with feedback.
Concentrating Treatment to High-volume Centres
A growing number of studies report variation in outcomes between institutions providing healthcare. For cancer surgery in particular, a relationship exists between hospital or surgical volume and patient outcomes in terms of operative mortality, complications and overall survival. 13 In most western healthcare systems, efforts are made to reduce this hospital variation. Most initiatives focus on selective referral, encouraging patients to seek care in high-volume hospitals.
A strategy whereby a larger proportion of patients is treated in specialised centres could evidently improve overall results for complex surgical procedures such as oesophagectomies and pancreatectomies. 14 Although there are also multiple studies showing a positive volume-outcome relationship for colon and rectal cancer, [15] [16] [17] variation is smaller compared with oesophagectomies or pancreatectomies. Besides, one must keep in mind that there are also low-volume providers who perform very well and high-volume providers with unacceptable outcomes. In addition, the expertise for diagnosis and treatment of common types of cancer should preferably be widespread and easily accessible for all patients.
National Audits
As an alternative to volume-based referral, hospitals and surgeons might improve their results by learning from their own outcome statistics and those of colleagues treating a similar patient group.
Surgical audit is a quality instrument that collects detailed clinical data from different healthcare providers, which can be adjusted for baseline risk and subsequently fed back to individual hospitals or surgeons. Identifying, communicating and adopting 'best practices'
might improve the quality of care nationwide. 18 An important condition for the success of outcome registries is the quality of the collected data. Data have to be prospective, complete, case-mixadjusted and, preferably, collected by independent investigators. 19 In addition, the quality of the data has to be assured by a second independent registry.
In Europe, several national rectal cancer audit registries have been established since the 1990s (see Table 1 ). Colorectal Cancer 
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Although all national audits and trial populations described above achieved excellent results, there remain differences between European countries that cannot be explained easily (see Table 2 ).
On review of the results of the national audits, the 30-day mortality rate ranges from 2.4% (Sweden 22 ) to 5% (Denmark 24 and the UK 25 ).
Although the differences in five-year survival are definitely getting smaller than before auditing, the proportions still range from 55% The Netherlands. 20 To generate the best care for rectal cancer in the whole of Europe and to meet political and public demands for transparency, a deep and broad insight into the results of rectal cancer treatment is needed in all nations. The inevitable conclusion is that a European audit registration is needed to ameliorate the treatment of rectal cancer even further and decrease variation in quality of care. Urged by these arguments, the European Society of Surgical Oncology initiated an international, multidisciplinary, outcome-based quality improvement programme, which has been fully embraced by the European CanCer Organisation (ECCO). ECCO has set the goal to "Uphold the right of all European cancer patients to the best possible treatment and care". Registration of outcome-based quality measurements will provide transparency, benchmarking and internal feedback, which will rapidly lead to improvements in cancer care. In this article we have described the direct, measurable improvements that have been made by national audit initiatives to improve quality European Audit on Colorectal Cancer Treatment Outcome Figure 1) .
Initially, the focus will be on colorectal cancer because of the experience in quality measurement and the already existing audit registrations. The project consists of two parts. In the first period of two years the registration will make use of currently existing audit systems for colorectal cancer as in Norway, Sweden, Denmark, the UK, The Netherlands and Belgium and start a benchmarking process.
The national audit co-ordinators will provide access to their national databases and will form a multidisciplinary steering committee. The second period starts after development of the European registration system. The data will be used continuously for benchmarking and internal feedback among participants. Afterwards, this experience will be used to extend the audit to other solid malignancies such as breast, gastric and oesophageal cancer.
Conclusion
Recent developments in quality assurance in surgical oncology have resulted in improvements that have a greater impact on survival than those of any of the adjuvant therapies currently under study. A European audit could advance future improvements and spread these to every cancer patient in Europe. ECCO has recognised the importance of quality assurance and has created a framework to develop a European audit. 
